|
Short Title: MK-2870-032
Enrollment Status: Recruiting
NCT #: NCT06966700
Specialty Area: Oncology
Conditions Studied: Early Stage; High-Risk Breast Cancer
Age Groups: Adult; Older Adult
Phase: III
To find out if adding sacituzumab tirumotecan to pembrolizumab and chemotherapy helps eliminate cancer cells before surgery and improves long-term outcomes for people with high-risk, early-stage triple-negative or HR-low positive/HER2-negative breast cancer.
Location: Renown Health, Office of Clinical Research
Address:
Complete Study Details: https://clinicaltrials.gov/study/NCT06966700
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.
